394 related articles for article (PubMed ID: 26314515)
21. Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents.
van den Brink W; Emerenciana A; Bellanti F; Della Pasqua O; van der Laan JW
Toxicol Appl Pharmacol; 2017 Apr; 320():51-59. PubMed ID: 28213092
[TBL] [Abstract][Full Text] [Related]
22. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
Potts JE; Gray LJ; Brady EM; Khunti K; Davies MJ; Bodicoat DH
PLoS One; 2015; 10(6):e0126769. PubMed ID: 26121478
[TBL] [Abstract][Full Text] [Related]
23. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
Hernández C; Bogdanov P; Corraliza L; García-Ramírez M; Solà-Adell C; Arranz JA; Arroba AI; Valverde AM; Simó R
Diabetes; 2016 Jan; 65(1):172-87. PubMed ID: 26384381
[TBL] [Abstract][Full Text] [Related]
24. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
Sun W; Shi Y; Lee WC; Lee SY; Long F
Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1.
Jin YR; Stohn JP; Wang Q; Nagano K; Baron R; Bouxsein ML; Rosen CJ; Adarichev VA; Lindner V
Bone; 2017 Apr; 97():153-167. PubMed ID: 28115279
[TBL] [Abstract][Full Text] [Related]
26. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
27. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.
Nuche-Berenguer B; Moreno P; Portal-Nuñez S; Dapía S; Esbrit P; Villanueva-Peñacarrillo ML
Regul Pept; 2010 Jan; 159(1-3):61-6. PubMed ID: 19586609
[TBL] [Abstract][Full Text] [Related]
28. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis.
Koehler JA; Baggio LL; Cao X; Abdulla T; Campbell JE; Secher T; Jelsing J; Larsen B; Drucker DJ
Diabetes; 2015 Mar; 64(3):1046-56. PubMed ID: 25277394
[TBL] [Abstract][Full Text] [Related]
30. Increased Osteoblastic Cxcl9 Contributes to the Uncoupled Bone Formation and Resorption in Postmenopausal Osteoporosis.
Liu Z; Liang W; Kang D; Chen Q; Ouyang Z; Yan H; Huang B; Jin D; Chen Y; Li Q
Clin Interv Aging; 2020; 15():1201-1212. PubMed ID: 32764906
[TBL] [Abstract][Full Text] [Related]
31. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
[TBL] [Abstract][Full Text] [Related]
32. Positive regulation of osteogenesis by bile acid through FXR.
Cho SW; An JH; Park H; Yang JY; Choi HJ; Kim SW; Park YJ; Kim SY; Yim M; Baek WY; Kim JE; Shin CS
J Bone Miner Res; 2013 Oct; 28(10):2109-21. PubMed ID: 23609136
[TBL] [Abstract][Full Text] [Related]
33. Fast and long acting neoflavonoids dalbergin isolated from Dalbergia sissoo heartwood is osteoprotective in ovariectomized model of osteoporosis: Osteoprotective effect of Dalbergin.
Choudhary D; Kushwaha P; Gautam J; Kumar P; Verma A; Kumar A; Maurya SW; Siddiqui IR; Mishra PR; Maurya R; Trivedi R
Biomed Pharmacother; 2016 Oct; 83():942-957. PubMed ID: 27522257
[TBL] [Abstract][Full Text] [Related]
34. Differential response of bone and kidney to ACEI in db/db mice: A potential effect of captopril on accelerating bone loss.
Zhang Y; Li XL; Sha NN; Shu B; Zhao YJ; Wang XL; Xiao HH; Shi Q; Wong MS; Wang YJ
Bone; 2017 Apr; 97():222-232. PubMed ID: 28130181
[TBL] [Abstract][Full Text] [Related]
35. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
[TBL] [Abstract][Full Text] [Related]
36. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.
Koehler JA; Baggio LL; Lamont BJ; Ali S; Drucker DJ
Diabetes; 2009 Sep; 58(9):2148-61. PubMed ID: 19509017
[TBL] [Abstract][Full Text] [Related]
37. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
38. Targeted overexpression of osteoactivin in cells of osteoclastic lineage promotes osteoclastic resorption and bone loss in mice.
Sheng MH; Wergedal JE; Mohan S; Amoui M; Baylink DJ; Lau KH
PLoS One; 2012; 7(4):e35280. PubMed ID: 22536365
[TBL] [Abstract][Full Text] [Related]
39. The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.
Nakatani T; Chen T; Johnson J; Westendorf JJ; Partridge NC
J Bone Miner Res; 2018 Jul; 33(7):1362-1375. PubMed ID: 29544022
[TBL] [Abstract][Full Text] [Related]
40. Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis.
Cameron-Vendrig A; Reheman A; Siraj MA; Xu XR; Wang Y; Lei X; Afroze T; Shikatani E; El-Mounayri O; Noyan H; Weissleder R; Ni H; Husain M
Diabetes; 2016 Jun; 65(6):1714-23. PubMed ID: 26936963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
